Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.

Abstract:

:Immune suppression is a hallmark of multiple myeloma (MM), but data on soluble factors involved in the fate of immune effector cells are limited. The CXCR3-binding chemokine monokine induced by interferon-gamma (MIG/CXCL9) has been associated with tumor progression, immune escape, and angiogenesis in several malignancies. We here aimed to evaluate the prognostic relevance of MIG in MM. MIG serum levels were significantly elevated in newly diagnosed MM patients (n = 105) compared to patients with monoclonal gammopathy of undetermined significance (MGUS; n = 17) and healthy controls (n = 37). MIG expression in stromal compartments but not purified MM cells correlated with serum levels. High MIG serum levels were significantly associated with established prognostic markers (international staging system: R = 0.25, p = 0.001; age: R = 0.47, p < 0.0001; lactate-dehydrogenase: R = 0.34, p = 0.0005) and poor overall survival (OS) (median OS 17.0 months vs. not reached, p < 0.001). A similar association was found for CXCL10 and CXCL11. Multivariate regression analysis indicated MIG as an independent prognostic factor of OS.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Bolomsky A,Schreder M,Hübl W,Zojer N,Hilbe W,Ludwig H

doi

10.3109/10428194.2016.1151511

subject

Has Abstract

pub_date

2016-11-01 00:00:00

pages

2516-25

issue

11

eissn

1042-8194

issn

1029-2403

journal_volume

57

pub_type

杂志文章
  • Association of familial leukemia with HLA Cw3: is it real?

    abstract::A kindred with familial leukemia is described in which three members are affected by leukemia in three consecutive generations. One of these members had Philadelphia positive chronic myeloid leukemia (CML) and other two had precursor B acute lymphoblasticleukemia (ALL)--Philadelphia negative. All three of them shared ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000035707

    authors: Kuruvilla J,Gupta V,Gill KS,Lipton JH

    更新日期:2003-02-01 00:00:00

  • Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies.

    abstract::The standard of therapy for the high risk adult neutropenic host being treated with broad spectrum antibiotics for fever has been to continue intravenous antibiotics until neutropenia resolves. We performed a small, limited pilot study to determine if it is safe to switch these patients to oral monotherapy with ciprof...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199609054816

    authors: Horowitz HW,Holmgren D,Seiter K

    更新日期:1996-09-01 00:00:00

  • Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes.

    abstract::Severe myelosuppression is one of the major adverse effects of Idarubicin (IDA). Especially, after two sequential therapy courses, IDA showed a stronger myelosuppression than after the first course. IDA was metabolized in liver by carbonyl reducing enzymes (CRE) to its 13-OH metabolite, idarubicinol(IDAol),which is mo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190801947526

    authors: Yamashita T,Fukushima T,Ueda T

    更新日期:2008-04-01 00:00:00

  • Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I.

    abstract::Therapy with an immunotoxin, anti-Tac(Fv)-PE38, which is a conjugate of the variable domains of an anti-Tac monoclonal antibody and Pseudomonas exotoxin, was reported to be useful for adult T cell leukemia (ATL) patients but a considerable amount of the immunotoxin is needed for the therapy and some side effects were ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290017042

    authors: Ohno N,Kreitman RJ,Saito T,Masamoto I,Uozumi K,Hanada S,Takeuchi S,Furukawa T,Sumizawa T,Arima T,Akiyama S

    更新日期:2002-04-01 00:00:00

  • Diversity in antibody-based approaches to non-Hodgkin lymphoma.

    abstract::Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for approximately 85% of all cases of NHL, and are commonly treated with chemotherapy, or monoclonal antibodies (mAbs) that target CD20 antigens on the surface...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2010.500047

    authors: Maloney D,Morschhauser F,Linden O,Hagenbeek A,Gisselbrecht C

    更新日期:2010-08-01 00:00:00

  • Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.

    abstract::Preclinical studies suggest that bortezomib, through inhibition of nuclear factor-κB (NF-κB) activation, may enhance the effects of radioimmunotherapy. This phase I trial was designed to determine the maximum tolerated dose (MTD) of weekly bortezomib induction combined with Y-90-ibritumomab tiuxetan followed at the ti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.722215

    authors: Roy R,Evens AM,Patton D,Gallot L,Larson A,Rademaker A,Cilley J,Spies S,Variakojis D,Gordon LI,Winter JN

    更新日期:2013-03-01 00:00:00

  • Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.

    abstract::Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600565057

    authors: Faber E,Nausová J,Jarosová M,Egorin MJ,Holzerová M,Rozmanová S,Maresová I,Divoký V,Indrák K

    更新日期:2006-06-01 00:00:00

  • The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients.

    abstract::Anamorsin is a cell-death-defying factor, which was originally isolated as a molecule that conferred resistance to apoptosis induced by growth factor starvation. In order to evaluate anamorsin expression levels in malignant lymphoma, we immunostained paraffin-embedded sections with anti-anamorsin monoclonal antibodies...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701713697

    authors: Shizusawa T,Shibayama H,Murata S,Saitoh Y,Sugimoto Y,Matsumura I,Ogawa H,Sugiyama H,Fukuhara S,Hino M,Kanamaru A,Yamauchi A,Aozasa K,Kanakura Y

    更新日期:2008-01-01 00:00:00

  • Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF).

    abstract::The aim of the present study was to evaluate the efficacy of the combination of fludarabine 30/mg/m2 + cytarabine 2g/m2 followed by the administration of G-CSF to achieve a complete remission (CR) in patients with relapsed acute lymphoblastic leukemia (ALL). We treated twelve patients in first relapse, overall 10 pati...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199709039047

    authors: Montillo M,Tedeschi A,Centurioni R,Leoni P

    更新日期:1997-05-01 00:00:00

  • The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB.

    abstract::This study investigated expression profiles of tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) pathway components and mechanisms underlying TRAIL-induced apoptosis in mucosa associated lymphoid tissue (MALT) lymphoma. Genetic aberrations including translocations and trisomies were assessed by rev...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.953149

    authors: Anees M,Horak P,Schiefer AI,Vaňhara P,El-Gazzar A,Perco P,Kiesewetter B,Müllauer L,Streubel B,Raderer M,Krainer M

    更新日期:2015-05-01 00:00:00

  • Microsatellite instability indicative of defects in the major mismatch repair genes is rare in patients with B-cell chronic lymphocytic leukemia: Evaluation with disease stage and family history.

    abstract::A possible role for DNA mismatch repair defects and microsatellite instability (MSI) in the pathogenesis of a number of B-cell lymphoproliferative disorders has recently been debated. To gain further insight into the impact of MSI on B-CLL, we evaluated samples from a series of 982 patients using the mono-satellite ma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701361844

    authors: Sellick GS,Lubbe SJ,Matutes E,Catovsky D,Houlston RS

    更新日期:2007-07-01 00:00:00

  • Current and future immunotherapeutic approaches in Hodgkin lymphoma.

    abstract::Hodgkin lymphoma (HL) has become a highly curable malignancy even in advanced stages when treated adequately. However, relapsed or refractory disease and treatment-related toxicity constitute a significant clinical challenge. Innovative approaches are thus needed to improve treatment of these mainly young patients. In...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1185789

    authors: Bröckelmann PJ,Borchmann P,Engert A

    更新日期:2016-09-01 00:00:00

  • Analysis of chromosome 6q deletion in EBV-associated NK cell leukaemia/lymphoma.

    abstract::Deletions involving chromosome 6q have been reported in a number of human cancers such as ovarian and breast tumours as well as haematopoietic malignancies. It seems that this region might contain tumour-suppressor genes. Putative natural killer cell lymphomas/leukaemias (NKLL) represent a group of recently characteri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290006062

    authors: Ohshima K,Haraokaa S,Ishihara S,Ohgami A,Yoshioka S,Suzumiya J,Kikuchi M

    更新日期:2002-02-01 00:00:00

  • Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.

    abstract::Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.627480

    authors: Nicolini FE,Masszi T,Shen Z,Gallagher NJ,Jootar S,Powell BL,Dorlhiac-Llacer PE,Zheng M,Szczudlo T,Turkina A

    更新日期:2012-05-01 00:00:00

  • Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.

    abstract::Extranodal natural killer (NK)/T-cell lymphoma is an aggressive lymphoid tumor. Optimal treatment strategies have not yet been fully defined. To explore a more effective treatment, we conducted sequential chemoradiotherapy (SCRT) and evaluated the safety and efficacy. Seventy-eight patients (51 males, 27 females) were...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1108415

    authors: Dong LH,Zhang LJ,Wang WJ,Lei W,Sun X,Du JW,Gao X,Li GP,Li YF

    更新日期:2016-07-01 00:00:00

  • Megakaryocytic leukemia and platelet factor 4.

    abstract::The de novo megakaryocytic leukemia fulfilling the FAB criteria is still an uncommonly recognized variant of acute leukemia. Many studies have shown that the megakaryocytic leukemic events may occur at a pluripotent stem cell level and clinical observations reveal that the megakaryocytic leukemias are diverse entities...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209051011

    authors: Ryo R,Yasunaga M,Saigo K,Yamaguchi N

    更新日期:1992-11-01 00:00:00

  • Vaccination with immunoglobulin frame region-derived nonapeptide elicits cellular immune response against lymphoma in human leukocyte antigen-A2.1 transgenic mice.

    abstract::The epitope in the frame region (FR) of the immunoglobulin heavy chain variable region (IgHV) is a potential target for lymphoma immunotherapy. Our previous work identified a FR-derived nonapeptide (QLVQSGAEV) capable of in vitro eliciting anti-lymphoma specific cytotoxic T lymphocytes (CTLs) in lymphocytes from human...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.577257

    authors: Liu H,Cai P,Liu HX,Wang JL,Liu Q,Zhu P

    更新日期:2011-09-01 00:00:00

  • Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia.

    abstract::Opportunistic infection with invasive aspergillosis (IA) is increasingly frequent in immunocompromised patients, particularly in those with hematological malignancies. In this setting, IA typically involves the lung, with extra-pulmonary involvement usually occurring in the setting of disseminated infection. We report...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190400025138

    authors: Chionh F,Herbert KE,Seymour JF,Prince HM,Wolf M,Zimet A,Tam C,Kennedy GA

    更新日期:2005-04-01 00:00:00

  • Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus.

    abstract::Abstract Everolimus (RAD-001) has recently been used as an immunosuppressive drug to treat patients after hematopoietic stem cell transplant (HSCT), thereby reducing cyclosporine-related nephrotoxicity. We studied the immunomodulatory effect of everolimus on mitogen-stimulated and particularly cytomegalovirus (CMV)-sp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.822496

    authors: Jin N,Malcherek G,Mani J,Zurleit R,Schmitt A,Chen B,Freund M,Ho AD,Schmitt M

    更新日期:2014-05-01 00:00:00

  • Techniques for detection of minimal residual disease.

    abstract::Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characte...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509075308

    authors: Carlo-Stella C,Mangoni L,Dotti GP,Rizzoli V

    更新日期:1995-01-01 00:00:00

  • Multiple myeloma presenting clinically as lymphoma.

    abstract::Multiple myeloma typically presents with monoclonal proteinemia, marrow plasmacytosis, anemia, bony involvement, hypercalcemia and renal insufficiency. Less frequent presentations include hepatic and splenic enlargement (5% of cases), lymphadenopathy (4%) and biclonal gammopathy (1%). Chemotherapy may produce remissio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709058347

    authors: Daeninck PJ,Williams GJ,Rubinger M,Johnston JB

    更新日期:1997-12-01 00:00:00

  • Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence.

    abstract::Infection with the Epstein-Barr virus (EBV) is common worldwide. A significant number of infected individuals develop infectious mononucleosis (IM). IM is manifested in most patients as a benign disease with mild symptoms. However, serious complications may develop in a subset of patients. Because EBV-infected B lymph...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809057570

    authors: Wright-Browne V,Schnee AM,Jenkins MA,Thall PF,Aggarwal BB,Talpaz M,Estrov Z

    更新日期:1998-08-01 00:00:00

  • Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.

    abstract::The prednisone, etoposide, procarbazine and cyclophosphamide (PEP-C) oral combination chemotherapy regimen (prednisone 20 mg, cyclophosphamide 50 mg, etoposide 50 mg, and procarbazine 50 mg with an oral anti-emetic) was employed at our center to treat 22 patients with heavily pretreated, recurrent mantle cell lymphoma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701837330

    authors: Coleman M,Martin P,Ruan J,Furman R,Niesvizky R,Elstrom R,George P,Leonard J,Kaufmann T

    更新日期:2008-03-01 00:00:00

  • Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

    abstract::Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk A...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1594214

    authors: Beyar-Katz O,Lavi N,Ringelstein-Harlev S,Henig I,Yehudai-Ofir D,Haddad N,Fineman R,Ofran Y,Nov Y,Sahar D,Moustafa-Hawash N,Rowe JM,Zuckerman T

    更新日期:2019-10-01 00:00:00

  • Human NK cells in health and disease: clinical, functional, phenotypic and DNA genotypic characteristics.

    abstract::Natural killer (NK) cells are the subject of great current interest because of their possible (in vivo) role in tumour cell surveillance and killing, and because of the potential application of cytokine-modulated NK cells in cancer immunotherapy. In addition, clonal proliferations of NK-associated (NKa) cell populatio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209049794

    authors: Richards SJ,Scott CS

    更新日期:1992-08-01 00:00:00

  • Novel agents versus chemotherapy as frontline treatment of CLL.

    abstract::Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1280606

    authors: Piggin A,Bayly E,Tam CS

    更新日期:2017-06-01 00:00:00

  • Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.

    abstract::131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia (CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN gamma. In study, 1, 13 not pretreated and 41 pretreated patients, 48 in chronic phase disease, 6 in accelerated phase, received 4 x 10(6) U/m2 IFN a...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428199309148513

    authors: Niederle N,Kloke O,Wandl UB,Becher R,Moritz T,Opalka B

    更新日期:1993-01-01 00:00:00

  • Human B cell lymphomas: in vitro and in vivo studies on growth factors and cell growth.

    abstract::The B cell non-Hodgkin's lymphomas (NHL-B) are a common, but heterogeneous group of human lymphoid neoplasms, consisting of monoclonal populations of neoplastic B lymphocytes demonstrating non-random chromosomal abnormalities, often associated with proto-oncogene translocations. Clinically and pathologically, these ly...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309149112

    authors: Ford RJ,Tamayo A,Li DJ,Cabanillas F

    更新日期:1993-01-01 00:00:00

  • Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database.

    abstract::B-lineage acute lymphoblastic leukemia (B-ALL) in the elderly population is generally considered to have a poor prognosis. It is unclear whether their survival has improved in the current era. Using the Surveillance, Epidemiology, and End Results database, we selected 717 elderly patients (age≥60) with B-ALL diagnosed...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.991921

    authors: Guru Murthy GS,Venkitachalam R,Mehta P

    更新日期:2015-01-01 00:00:00

  • Acute promyelocytic leukemia in a HIV seropositive patient.

    abstract::Acute myeloid leukemia (AML) is infrequent in patients with human immunodeficiency virus (HIV) infection. Among AML, acute promyelocytic leukemia (APL) has been rarely described in such patients, with only one case being published. We report a 30 years-old intravenous drug abuser HIV-infected male with APL who attaine...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709050899

    authors: Calvo R,Ribera JM,Battle M,Sancho JM,Granada I,Flores A,Millá F,Feliu E

    更新日期:1997-08-01 00:00:00